PEPPER Trial: Aspirin May Be a Viable Option After Hip or Knee Replacement

Aspirin remains a viable option for preventing blood clots after hip or knee replacement surgery, despite failing to prove non-inferiority to anticoagulants in a large clinical trial.

The study, involving nearly 19,000 patients, suggests that while anticoagulants may reduce symptomatic events, their absolute benefit must be weighed against bleeding risks.

  • Aspirin did not strictly meet the statistical threshold to be considered “as good as” warfarin or rivaroxaban for preventing clots, but the clinical differences in outcomes were small.
  • Anticoagulants carry a slightly higher risk of wound-related complications and bleeding compared to aspirin monotherapy.

The Pulmonary Embolism Prevention after Hip and Knee Replacement (PEPPER) trial, published in the New England Journal of Medicine, tracked 18,883 patients undergoing elective arthroplasty across the United States and Canada.

Researchers evaluated aspirin (81 mg twice daily) against warfarin (to a target international normalised ratio of 2.0) and rivaroxaban (10 mg daily) over a 30-day period. The primary endpoint—a composite of death or symptomatic venous thromboembolism (VTE)—occurred in 1.26% of the aspirin group, compared to 1.23% for warfarin and 0.94% for rivaroxaban.

Can Aspirin Alone Prevent Clots After Joint Replacement? — Latest Medical Papers

Because the aspirin group did not meet the predefined non-inferiority margin of 0.69 percentage points against the anticoagulants, the trial could not definitively label aspirin as an equivalent substitute. However, safety data provided a different perspective.

The risk of primary safety events—including major bleeding and wound complications—was numerically lower in the aspirin group (2.91%) than in the warfarin (3.36%) or rivaroxaban (3.48%) groups, as reported in the New England Journal of Medicine trial findings.

The clinical landscape is further nuanced by the EPCAT III study, also published in the New England Journal of Medicine. That research found that aspirin alone was non-inferior to a strategy of rivaroxaban followed by aspirin for preventing symptomatic VTE. The EPCAT III results showed that symptomatic proximal deep vein thrombosis (DVT) or pulmonary embolism occurred in 0.48% of the aspirin-alone group and 0.45% of the rivaroxaban-aspirin group.

Aspirin vs anticoagulants in hip/knee: neither noninferior — AudioScholar
Treatment Regimen Incidence of Death/VTE (6-Month) Primary Safety Events (6-Month)
Aspirin (81 mg BID) 1.26% 2.91%
Warfarin (Target INR 2.0) 1.23% 3.36%
Rivaroxaban (10 mg Daily) 0.94% 3.48%

In an accompanying editorial, haematologist Associate Professor John Eikelboom of McMaster University said that while anticoagulants appear to prevent more symptomatic events, the absolute benefit is likely tied to a patient’s baseline risk. “Anticoagulants appear to prevent additional symptomatic events, and their absolute benefit is likely to be greater with increasing baseline thrombotic risk,” Eikelboom wrote in the editorial commentary.

He emphasized that the challenge remains identifying which patients benefit from more than aspirin, particularly because patients at the highest thrombotic risk were underrepresented in these trials.

Identifying the patients in whom the benefit of anticoagulants outweighs potential increases in the risks of bleeding and wound complications remains challenging, according to the editorial. Patients who experience concerning symptoms after surgery should seek medical evaluation.

“The question is no longer whether aspirin works but which patients may benefit from more than aspirin,” Eikelboom concluded.

Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

4K Blu-ray Discounts Expected Ahead of November 27 Black Friday

New International Student Enrollment Falls 15% at U.S. Colleges